Adaptimmune Therapeutics Plc (ADAP) — Cash Flow-to-Debt Ratio
Adaptimmune Therapeutics Plc (ADAP) has a Cash Flow-to-Debt Ratio of -0.17x as of June 2025, meaning its operating cash flow of $-34.78 Million could theoretically repay 0% of its total liabilities ($201.59 Million) in one year. See Adaptimmune Therapeutics Plc (ADAP) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Adaptimmune Therapeutics Plc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Adaptimmune Therapeutics Plc across 13 annual periods. Also explore ADAP year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Adaptimmune Therapeutics Plc (2012–2024)
Year-by-year debt coverage analysis for Adaptimmune Therapeutics Plc. For market capitalisation and broader financial context, see ADAP stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.31x | $-73.21 Million | $234.11 Million | ▲ +46.0% |
| 2023 | -0.58x | $-140.88 Million | $243.10 Million | ▼ -1.0% |
| 2022 | -0.57x | $-141.77 Million | $247.04 Million | ▼ -1509.9% |
| 2021 | 0.04x | $10.73 Million | $263.58 Million | ▲ +108.3% |
| 2020 | -0.49x | $-53.59 Million | $109.92 Million | ▲ +74.9% |
| 2019 | -1.94x | $-112.51 Million | $57.91 Million | ▲ +44.4% |
| 2018 | -3.50x | $-104.39 Million | $29.85 Million | ▼ -403.2% |
| 2017 | -0.69x | $-54.31 Million | $78.16 Million | ▲ +1.4% |
| 2016 | -0.70x | $-48.17 Million | $68.37 Million | ▲ +11.6% |
| 2015 | -0.80x | $-32.74 Million | $41.07 Million | ▼ 0.0% |
| 2014 | -0.80x | $-32.74 Million | $41.07 Million | ▼ -213.7% |
| 2013 | 0.70x | $37.23 Million | $53.11 Million | ▲ +135.8% |
| 2012 | -1.96x | $-7.77 Million | $3.97 Million | — |